|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Prasugrel#Adverse Reactions]] |
| {{Prasugrel}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Adverse Reactions==
| |
| | |
| ===Clinical Trials Experience===
| |
| | |
| The following serious adverse reactions are also discussed elsewhere in the labeling:
| |
| | |
| *Bleeding [see Boxed Warning and Warnings and Precautions (5.1, 5.2)]
| |
| *Thrombotic thrombocytopenic purpura [see Warnings and Precautions (5.4)]
| |
| | |
| Safety in patients with ACS undergoing PCI was evaluated in a [[clopidogrel]]-controlled study, TRITON-[[TIMI]] 38, in which 6741 patients were treated with Effient (60-mg loading dose and 10-mg once daily) for a median of 14.5 months (5802 patients were treated for over 6 months; 4136 patients were treated for more than 1 year). The population treated with Effient was 27 to 96 years of age, 25% female, and 92% Caucasian. All patients in the TRITON-[[TIMI]] 38 study were to receive [[aspirin]]. The dose of [[clopidogrel]] in this study was a 300-mg loading dose and 75-mg once daily.
| |
| | |
| Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials cannot be directly compared with the rates observed in other clinical trials of another drug and may not reflect the rates observed in practice.
| |
| | |
| ====Drug Discontinuation====
| |
| | |
| The rate of study drug discontinuation because of adverse reactions was 7.2% for Effient and 6.3% for [[clopidogrel]]. Bleeding was the most common adverse reaction leading to study drug discontinuation for both drugs (2.5% for Effient and 1.4% for [[clopidogrel]]).
| |
| | |
| ====Bleeding====
| |
| | |
| Bleeding Unrelated to [[CABG]] Surgery - In TRITON-[[TIMI]] 38, overall rates of [[TIMI]] Major or Minor bleeding adverse reactions unrelated to coronary artery bypass graft surgery ([[CABG]]) were significantly higher on Effient than on [[clopidogrel]], as shown in Table 1.
| |
| | |
| {|
| |
| |-
| |
| |[[File:Prasugrel02.jpg|thumb|800px]]
| |
| |-
| |
| |}
| |
| | |
| Figure 1 demonstrates non-[[CABG]] related [[TIMI]] Major or Minor bleeding. The bleeding rate is highest initially, as shown in Figure 1 (inset: Days 0 to 7) [see Warnings and Precautions (5.1)].
| |
| | |
| Bleeding by Weight and Age - In TRITON-[[TIMI]] 38, non-[[CABG]]-related [[TIMI]] Major or Minor bleeding rates in patients with the risk factors of age ≥75 years and weight <60 kg are shown in Table 2.
| |
| | |
| {|
| |
| |-
| |
| |[[File:Prasugrel05.jpg|thumb|800px]]
| |
| |-
| |
| |}
| |
| | |
| Bleeding Related to [[CABG]] - In TRITON-[[TIMI]] 38, 437 patients who received a thienopyridine underwent [[CABG]] during the course of the study. The rate of [[CABG]]-related [[TIMI]] Major or Minor bleeding was 14.1% for the Effient group and 4.5% in the [[clopidogrel]] group (see Table 3). The higher risk for bleeding adverse reactions in patients treated with Effient persisted up to 7 days from the most recent dose of study drug.
| |
| | |
| {|
| |
| |-
| |
| |[[File:Prasugrel03.jpg|thumb|800px]]
| |
| |-
| |
| |}
| |
| | |
| Bleeding Reported as Adverse Reactions - Hemorrhagic events reported as adverse reactions in TRITON-[[TIMI]] 38 were, for Effient and [[clopidogrel]], respectively: [[epistaxis]] (6.2%, 3.3%), [[gastrointestinal hemorrhage]] (1.5%, 1.0%), [[hemoptysis]] (0.6%, 0.5%), [[subcutaneous hematoma]] (0.5%, 0.2%), post-procedural hemorrhage (0.5%, 0.2%), [[retroperitoneal hemorrhage]] (0.3%, 0.2%), [[pericardial effusion]]/hemorrhage/tamponade (0.3%, 0.2%), and retinal hemorrhage (0.0%, 0.1%).
| |
| | |
| ====Malignancies====
| |
| | |
| During TRITON-[[TIMI]] 38, newly-diagnosed malignancies were reported in 1.6% and 1.2% of patients treated with prasugrel and [[clopidogrel]], respectively. The sites contributing to the differences were primarily colon and lung. In another Phase 3 clinical study of ACS patients not undergoing PCI, in which data for malignancies were prospectively collected, newly-diagnosed malignancies were reported in 1.8% and 1.7% of patients treated with prasugrel and [[clopidogrel]], respectively. The site of malignancies was balanced between treatment groups except for colorectal malignancies. The rates of colorectal malignancies were 0.3% prasugrel, 0.1% [[clopidogrel]] and most were detected during investigation of GI bleed or [[anemia]]. It is unclear if these observations are causally-related, are the result of increased detection because of bleeding, or are random occurrences.
| |
| | |
| ====Other Adverse Events====
| |
| | |
| In TRITON-[[TIMI]] 38, common and other important non-hemorrhagic adverse events were, for Effient and [[clopidogrel]], respectively: severe thrombocytopenia (0.06%, 0.04%), [[anemia]] (2.2%, 2.0%), abnormal hepatic function (0.22%, 0.27%), allergic reactions (0.36%, 0.36%), and [[angioedema ]](0.06%, 0.04%). Table 4 summarizes the adverse events reported by at least 2.5% of patients.
| |
| </div></div>
| |
| | |
| {|
| |
| |-
| |
| |[[File:Prasugrel04.jpg|thumb|800px]]
| |
| |-
| |
| |}
| |
| | |
| ===Postmarketing Experience===
| |
| | |
| The following adverse reactions have been identified during post approval use of Effient. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
| |
| | |
| Blood and lymphatic system disorders — [[Thrombocytopenia]], [[Thrombotic thrombocytopenic purpura]] ([[TTP]]) [see Warnings and Precautions (5.4) and Patient Counseling Information (17)]
| |
| | |
| Immune system disorders — Hypersensitivity reactions including anaphylaxis [see Contraindications (4.3)]<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5fe9c118-c44b-48d7-a142-9668ae3df0c6 | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5fe9c118-c44b-48d7-a142-9668ae3df0c6 | publisher = | date = | accessdate = 6 February 2014 }}</ref>
| |
| | |
| ==References==
| |
| | |
| {{Reflist|2}}
| |
| | |
| [[Category:Antiplatelet drugs]]
| |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |
| {{WikiDoc Help Menu}}
| |
| {{WikiDoc Sources}}
| |